Chemistry: analytical and immunological testing – Lipids – triglycerides – cholesterol – or lipoproteins
Reexamination Certificate
2005-08-24
2010-11-16
Gakh, Yelena G (Department: 1797)
Chemistry: analytical and immunological testing
Lipids, triglycerides, cholesterol, or lipoproteins
C436S173000
Reexamination Certificate
active
07833795
ABSTRACT:
The instant invention is drawn to methods and compositions useful for the assessment of cardiovascular risk in a mammal. The methods utilize biomarkers including prostanoid metabolites and isoprostanes as sensitive and stable markers of cardiovascular risk. The methods are particularly useful in a mammal that is contemplating undergoing coxib therapy, is undergoing coxib therapy, is undergoing antioxidant therapy, has ceased coxib therapy or has never undergone coxib therapy. The invention also includes kits useful for the assessment of cardiovascular risk in a mammal.
REFERENCES:
patent: 5891622 (1999-04-01), Morrow et al.
patent: 6727075 (2004-04-01), Fitzgerald et al.
patent: 6939718 (2005-09-01), Singh et al.
Mukherjee et al. “Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors”, Journal of American Medical Association, 2001, v. 286, No. 8, pp. 954-959.
Zhang et al. “COX-2-Dependent Cardiac Failure in Gh/tTG Transgenic Mice”, Circulation Research, Apr. 2003, v. 92, pp. 1153-1161.
Hennan et al. “Effect of Selective of Cyclooxygenase-2 Inhibiiton on Vascular Responses and Thrombosis in Canine Coronary Arteries”, Circulation, 2001, v. 104, pp. 820-825.
Knott et al. “Routine Prostaglanding Assya by DC-MS in Multiwell Tissue Culture Plates: Application to Human Synoviocytes and Chondrocytes”, Anal. Biochem., 1993, v. 210, No. 2, pp. 360-365, Abstract.
Mizugaki “Establishment of microanalysis of prostaglandin metabolites by GC/MS and its clincal application”, Yakugaku Zasshi, 1999, v. 119, No. 1, pp. 61-80, Abstract.
Domanski, “Cardiovascular risk assessment using pulse pressure in the first national health and nutrition examination survey (NHANES I)”, Hypertension, Oct. 1, 2001; 38(4): pp. 793-797.
Fitzpatrick et al. “Cardiovascular responses to PGI2 (prostacyclin) in the dog”, Circ. Res. 1978, v. 42, pp. 192-194.
Schwedhelm et al. “Application of Gas Chromatography-Mass Spectrometry for Analysis of Isoprostanes: Their Role in Cardiovascular Disease”, Clin Chem Lab Med 2003; v. 41, No. 12, pp. 1552-1561.
McAdam et al. “Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2”, Proc. Natl. Acad. Sci. USA, Jan. 1999, vol. 96, pp. 272-277.
Frishman, “Cyclooxygenase Inhibition in Patients With Coronary Artery Disease”, J. Am. Coll. Cardiol., Feb. 2004, v. 43, No. 4, pp. 532-533.
Audoly, L. P., et al., “Cardiovascular Responses to the Isoprostanes iPF2α-III and iPE2-III are Mediated via the Thromboxane A2Receptor In Vivo,”Circulation, vol. 101, pp. 2833-2840, 2000.
Awad, J. A., et al., “Identification Of Non-Cyclooxygenase-Derived Prostanoid (F2-Isoprostane) Metabolites in Human Urine And Plasma,”J. Biol. Chem., vol. 268, pp. 4161-4169, 1993.
Basu, S., “Radioimmunoassay of 8-Iso-Prostaglandin F2 Alpha: an Index for Oxidative Injury Via Free Radical Catalysed Lipid Peroxidation,,”Prost. Leuk. Ess. Fatty Acids., vol. 58, pp. 319-325, 1998.
Basu, S., “Oxidative Injury Induced Cyclooxygenase Activation in Experimental Hepatotoxicity,”Biochem. Biophys. Res. Commun., vol. 254, pp. 764-767, 1999.
Bombardier, C., et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients With Rheumatoid Arthritis,”N. Engl. J. Med., vol. 343, pp. 1520-1528, 2000.
Bourassa, P. A. K., et al., “Estrogen Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice,”Proc. Natl. Acad. Sci. USA, vol. 93, p. 10022-10027, 1996.
Carlson, S. H., et al., “Long-Term Telemetric Recording of Arterial Pressure and Heart Rate in Mice Fed Basal and High NaCl Diets,”Hypertension, vol. 35, pp. 1-5, 2000.
Carlson, S. H., et al., “Blood Pressure and NaC1-Sensitive Hypertension Are Influenced by Angiotensin-Converting Enzyme Gene Expression in Transgenic Mice,”Hypertension, vol. 39, pp. 214-218, 2002.
Catella, F., et al., “Paired Analysis of Urinary Thromboxane B2 Metabolites in Humans,”Thromb. Res. , vol. 47(6), pp. 647-656, 1987.
Catella, F., et al.,“11-Dehydrothromboxane B2: a Quantitative Index of Thromboxane A2Formation in the Human Circulation,”PNAS, vol. 83, pp. 5861-5865, 1986.
Catella-Lawson, F., et al., “Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids,”J. Pharmacol. Exp. Ther., vol. 289, pp. 735-741, 1999.
Catella-Lawson, F., et al., “Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,”N. Engl. J. Med., vol. 345, pp. 1809-1817, 2001.
Cayatte, A. J., et al., “The Thromboxane Receptor Antagonist S18886 but not Aspirin Inhibits Atherogenesis in Apo E-Deficient Mice Evidence That Eicosanoids Other Than Thromboxane Contribute to Atherosclerosis,”Arterioscler. Thromb. Vasc. Biol., Vo. 20, pp. 1724-1728, 2000.
Cesari, M., et al., “Inflammatory Markers and Onset of Cardiovascular Events Results from the Health ABC Study,”Circulation, vol. 108, pp. 2317-2322, 2003.
Cheng, Y., et al., “Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2,”Science, vol. 296, pp. 539-541, 2002.
Cheng, H. F., et al., “Cyclooxygenases, the Kidney, and Hypertension,”Hypertension, vol. 43, pp. 525-530, 2004.
Collins, P., et al., “17β-Estradiol Attenuates Acetylcholine-Induced Coronary Arterial Constriction in Women but Not Men With Coronary Heart Disease,”Circulation, vol. 92, pp. 24-30 1995.
Crofford, L. J., et al., “Thrombosis in Patients With Connective Tissue Diseases Treated With Specific Cyclooxygenase 2 Inhibitors. A Report of Four Cases,”Arthritis&Rheumatism, vol. 43(8), pp. 1891-1896, 2000.
Cullen, L., et al., “Selective Cyclooxygenase-2 Inhibition by Nimesulide in Man1,”J. Pharmacol. Exp. Ther., vol. 287, pp. 578-582, 1998.
Dannhardt, G., et al., , “Cyclooxygenase Inhibitors—Current Status And Future Prospects,”Eur. J. Med. Chem., vol. 36, pp. 109-126, 2001.
De Zwart, L. L., et al., “Biomarkers of Free Radical Damage Applications in Experimental Animals and in Humans,”Free Radic. Biol. Med., vol. 26(1-2), pp. 202-226, 1999.
Dietrich, H., et al., “Mouse Model of Transplant Arteriosclerosis Role of Intercellular Adhesion Molecule-1,”Arterioscler. Thromb. Vasc. Biol., vol. 20, pp. 343-352, 2000.
Dowd, N. P., et al., “Inhibition of Cyclooxygenase-2 Aggravates Doxorubicin-Mediated Cardiac Injury In Vivo,”J. Clin. Invest. , vol. 108, pp. 585-590, 2001.
Egan, K. M., et al., “COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice,”Science, vol. 306, pp. 1954-1957, 2004.
Egan, K. M., et al., “Cyclooxygenases, Thromboxane, and Atherosclerosis Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism,”Circulation, vol. 111, pp. 334-342, 2005.
Emery, J. D., et al., “Whole-Blood Platelet Aggregation Predicts In Vitro and In Vivo Primary Hemostatic Function in the Elderly,”Arterioscler. Thromb. Vasc. Biol., vol. 15, pp. 748-753, 1995.
Evans, W. E., et al., “Pharmacogenomics—Drug Disposition, Drug Targets, and Side Effects,”N. Engl. J. Med., vol. 348, pp. 538-549, 2003.
Fabre, J. E., et al., “Activation of the Murine EP3 Receptor for PGE2Inhibits Camp Production And Promotes Platelet Aggregation,”J. Clin. Invest., vol. 107, pp. 603-610, 2001.
Fitzgerald, G., et al., “The Coxibs, Selective Inhibitors of Cyclooxygenase-2,”N. Engl. J. Med., vol. 345, pp. 433-442, 2001.
Fitzgerald, G., et al., “Analysis of Prostacyclin and Thromboxane Biosynthesis in Cardiovascular Disease,”Circulation, vol. 67(6), pp. 1174-1177, 1983.
Fitzgerald, G., et al., “The Choreography of Cyclooxygenases in the Kidney,&
Drinker Biddle & Reath LLP
Gakh Yelena G
The Trustees of the University of Pennsylvania
LandOfFree
Assessment of cardiovascular risk using isoprostane... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assessment of cardiovascular risk using isoprostane..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assessment of cardiovascular risk using isoprostane... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252363